Blood Volume Assessment of Hepatocellular and Metastatic Carcinomas in the Liver
Blood Volume Assessment of Hepatocellular and Metastatic Carcinomas in the Liver
This project investigates the feasibility of assessing the relative blood volume of
 carcinomas in patients with Hepatocellular Carcinoma (HCC) and liver metastases from
 pancreatic or colorectal cancer compared to normal liver from DynaCT acquisitions on an
 interventional platform.
This project will enroll patients with non-diffuse liver disease who are candidates for chemo
 or radioembolization to treat or manage the disease during an image guided intervention.
 Subjects will undergo a CT perfusion study of the liver prior to the radioembolizaiton
 mapping procedure or prior to the chemoembolization treatment. During the radioembolization
 mapping or chemoembolization procedure, 2 DynaCT acquisitions on the interventional C-arm
 will be acquired (the second during an injection of an iodinated contrast material) and will
 be processed using Siemens' PBV software to generate blood volume maps. The diagnostic
 accuracy of the two approaches to assess the vascularity of the tumors will be assessed.
Inclusion Criteria:

 -  HCC or metastatic liver disease

 -  Candidate for radioembolization or chemoembolization

 Exclusion Criteria:

 -  Pregnant

 -  Iodine allergy